ANP
Antisense Therapeut
- Short interest
- 0.00%
- −0.01 pp 30d
- as of 24 July 2023
- Reported shorts
- 256
- Shares on issue
- 836.305M
Antisense Therapeut (ANP) company profile
Profile, insiders and operations
Company
AI-generated research profile of Antisense Therapeut
biotechnology
RNA therapeutics
drug development
genetic disorders
ASX
Antisense Therapeutics is a biotechnology company focused on developing RNA-based therapies for rare and debilitating genetic disorders. The company leverages antisense technology to create treatments that target specific genetic sequences, offering a unique approach to disease management. Positioned in the niche market of genetic disorder therapeutics, Antisense aims to address unmet medical needs with its innovative pipeline.
Director trades
No director trades found
ANP intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required